NCT02771340 2020-10-01
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Iconic Therapeutics, Inc.
Phase 1 Completed
Iconic Therapeutics, Inc.
Washington University School of Medicine
National Eye Institute (NEI)